BioTuesdays
Xenon Pharma

WB starts Xenon Pharma at OP; estimated fair value $27

William Blair initiated coverage of Xenon Pharmaceuticals (NASDAQ:XENE) with an “outperform” rating and estimated fair value of $27. The stock closed at $13.49 on Jan. 7. Xenon is focused on the development of selective...

ArcherDX names Mark Massaro as CFO

Closely-held ArcherDX appointed research industry veteran, Mark Massaro, as its CFO. “Mark’s extensive knowledge of the diagnostics landscape, coupled with his more than 20 years of industry experience, is...

X4 Pharma

HCW starts X4 Pharma at buy; PT $22

H.C. Wainwright launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $22 price target. The stock closed at $10.39 on Jan. 6. The company’s lead product candidate, mavorixafor, is a potential...

iBio Inc.

iBio initiates new litigation against Fraunhofer

iBio (NYSE AMERICAN:IBIO) filed a motion in the Court of Chancery of the State of Delaware to initiate new litigation against Fraunhofer-Gesellschaft through an amended complaint. The new motion asserts that depositions...

Titan Pharmaceuticals

Kate DeVarney joins Titan Pharma’s Board

Kate DeVarney, EVP and CSO of Titan Pharmaceuticals (NASDAQ:TTNP), was elected to the board at the company’s annual meeting. Dr. DeVarney, a clinical neuropsychologist by training, joined Titan in January...

Roth starts Crinetics Pharma at buy; PT $37

Roth Capital Partners launched coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a “buy” rating and $37 price target. The stock closed at $21.91 on Dec. 20. Crinetics is a clinical-stage pharmaceutical company...

BTIG cuts Valeritas Holdings to neutral; removes PT

BTIG downgraded Valeritas Holdings (NASDAQ:VLRX) to “neutral” from “buy” and removed its previous $10 price target after the company reduced its fourth quarter revenue guidance due to a temporary supply disruption and...

Roth starts Oxurion at buy; PT €9

Roth Capital Partners initiated coverage of Oxurion (Euronext Brussels:OXUR) with a “buy” rating and price target of €9. The stock was recently quoted at €2.41. “Our investment thesis is based on our understanding...

Subscribe

Sign up to our weekly BioTuesdays newsletter.